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http://dx.doi.org/10.1016/j.stemcr.2017.04.019SUMMARYBonemarrowmesenchymal stem/stromal cells (BM-MSCs) are key components of the hematopoietic niche thought to have a direct role
in leukemia pathogenesis. BM-MSCs from patients with acute myeloid leukemia (AML) have been poorly characterized due to disease
heterogeneity.We report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified
bymolecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. Stable MSC cultures were successfully
established and characterized from 40 of 46 AML patients irrespective of the risk subgroup. AML-derived BM-MSCs never harbored tu-
mor-specific cytogenetic/molecular alterations present in blasts, but displayed higher clonogenic potential than healthy donor (HD)-
derived BM-MSCs. Although HD- and AML-derived BM-MSCs equally provided chemoprotection to AML cells in vitro, AML-derived
BM-MSCsweremore immunosuppressive/anti-inflammatory, enhanced suppression of lymphocyte proliferation, and diminished secre-
tion of pro-inflammatory cytokines.Multivariate analysis revealed that the level of interleukin-10 produced by AML-derived BM-MSCs as
an independent prognostic factor negatively affected overall survival. Collectively our data show that AML-derived BM-MSCs are not
tumor related, but display functional differences contributing to therapy resistance and disease evolution.INTRODUCTION
Acute myeloid leukemia (AML) comprises a biologically
and genetically heterogeneous group of disorders charac-
terized by the rapid expansion of immature myeloid blasts
in bone marrow (BM) (Bene et al., 2015; Grimwade et al.,
2016). Disease heterogeneity is well documented and pa-
tients are stratified based on cytogenetic, molecular, and
immunophenotypic data. A significant proportion of pa-
tients fail to respond to standard first-line chemotherapy
regimens and current salvage therapy rarely yields durable
remissions, with relapse being common (Hills et al., 2016;
Medinger et al., 2016). Failure of current therapies
to eradicate leukemia-initiating cells and chemotherapy
refractoriness are major mechanisms underlying AML pro-
gression/relapse. The high rate of mortality and morbidityStem Cel
This is an open access article under the Cin AML guides the search for new compounds with higher
efficiency and lower toxicity.
Mesenchymal stem/stromal cells (MSCs) are an essential
component of the BM hematopoietic microenvironment
as well as a potential source of progenitors for mesodermal
tissues (Dominici et al., 2006; Garcia-Castro et al., 2008;
Horwitz et al., 2005; Pittenger et al., 1999). MSCs have
emerged as excellent candidates for clinical applications
due to their immunomodulatory properties and their abil-
ity to support normal hematopoiesis (Garcia-Castro et al.,
2008; Garcia-Gomez et al., 2010; Gonzalo-Gil et al., 2016;
Rodriguez et al., 2012; Sanchez et al., 2011). BM-MSCs
have been shown tomodulate hematopoiesis by regulating
the balance between self-renewal and differentiation of he-
matopoietic stem/progenitor cells (HSPCs) through cell-
cell interactions and paracrine secretion of cytokines andl Reports j Vol. 8 j 1573–1586 j June 6, 2017 j ª 2017 The Authors. 1573
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
extracellular matrix molecules (Konopleva et al., 2009).
Moreover, a role for BM-MSCs has been implied in the
pathogenesis of a variety of hematologic malignances
including acute lymphoblastic leukemia (ALL), AML, mul-
tiple myeloma (MM), lymphomas, chronic myeloid leuke-
mia (CML), and myelodysplastic syndromes (MDS) (Blau
et al., 2007, 2011; Corre et al., 2007; Lopez-Villar et al.,
2009; Medyouf et al., 2014; Menendez et al., 2009; Shala-
pour et al., 2010; Streubel et al., 2004;Walkley et al., 2007).
The interaction of leukemic cells with the BMmicroenvi-
ronment in functional niches is hypothesized to be amajor
mechanism underlying leukemia maintenance (Medyouf
et al., 2014; Schepers et al., 2015; Sison and Brown, 2011;
Tabe and Konopleva, 2014). BM stroma has also been sug-
gested to contribute to therapy resistance and promote re-
sidual disease and relapse by favoring leukemic cell growth
and clonal evolution of malignant cells (Iwamoto et al.,
2007; Konopleva et al., 2002).
To date, BM-MSCs from AML patients have been poorly
characterized, and conflicting results have made it unclear
whether or not these cells play a role in the disease and/or
treatment outcomes (Chandran et al., 2015; Geyh et al.,
2016; Klopp et al., 2011; Le et al., 2016; von der Heide
et al., 2016). To address these contradictions, we under-
took a functional, genetic, and immunological character-
ization of BM-MSC cultures from a cohort of 46 patients
with AML stratified into three risk groups according to
molecular/cytogenetic features: low-risk (LR), intermedi-
ate-risk (IR), and high-risk (HR) AML. Stable MSC cultures
were successfully established and characterized from the
BM of the majority AML patients irrespective of the mo-
lecular/cytogenetic subgroup. AML-derived BM-MSCs
from all molecular AML subgroups exhibited higher clo-
nogenic and in vitro immunosuppressive/anti-inflamma-
tory potential than BM-MSCs from healthy donors
(HDs), whereas only BM-MSCs derived from HR-AML
patients possessed a significantly reduced adipogenic/
osteogenic differentiation potential. Importantly, regard-
less of the molecular subgroup, all AML-derived BM-
MSC cultures were devoid of leukemia cell-specific cytoge-
netic/molecular alterations, verifying that HSPCs, rather
than pre-hematopoietic precursors, represent the cell of
origin in AML. Furthermore, multivariate analysis re-
vealed that the levels of the anti-inflammatory cytokine
interleukin-10 (IL-10) produced by AML-derived BM-
MSCs negatively affects overall survival (OS). Collectively,
we demonstrate that AML-derived BM-MSCs are not tu-
mor related but are functionally distinct from HD-derived
BM-MSCs. Importantly, our results provide a link between
in vitro properties of MSC and AML treatment outcomes,
providing clinical evidence that BM-MSCs play a role in
therapy responsiveness regardless of molecular/cytoge-
netic classification.1574 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017RESULTS
Functional Characterization of BM-MSCs from
Cytogenetically Distinct AML Subgroups
To characterize the MSC component of the BM stroma of
AML at presentation, we sought to generate stable BM-
MSC cultures from 46 patients with AML and ten age-
matched HDs. Table 1 shows the main biological and
molecular/cytogenetic features, allowing patient strat-
ification into LR-AML (n = 16, displaying favorable
cytogenetics/molecular features), IR-AML (n = 11, normal
karyotype and lacking mutations in NPM, FLT3, or cEBPa),
and HR-AML (n = 19, displaying unfavorable cytogenetics/
molecular features). Cultures of adherent fibroblast-like
cells were successfully established from the BM of AML pa-
tients using standard MSC culture conditions regardless of
cytogenetic/molecular subgroup or patient age (Figure 1A),
with cultures being generated at a high frequency from all
risk groups (81%, 91%, and 90% for LR-AML, IR-AML, and
HR-AML patients, respectively) (Table 2). To determine
whether these cells were bona fide MSCs, we compared
them againstMSCs derived from the BM of HDs using stan-
dardized criteria outlined by the International Society for
Cellular Therapy (ISCT) (Dominici et al., 2006). Similarly
to HD-derived BM-MSC, AML-derived cultures were consis-
tently devoid of contaminating hematopoietic and endo-
thelial cells, being negative for CD45, CD34, CD31, and
HLA-DR but expressing common MSC markers including
CD73, CD105, CD90, and CD13, as defined by ISCT guide-
lines on MSC characterization (Figure S1). Early passage
(p1–p3) BM-MSC cultures were further evaluated to mea-
sure their adipogenic and osteoblastic differentiation po-
tential. While all AML patient-derived BM-MSC cultures
demonstrated multipotent differentiating capacity, regard-
less of donor age, BM-MSC cultures from HR-AML patients
(complex karyotypes, TP53 mutated, FLT3-ITD+ or MLL-re-
arranged) possessed a very poor adipogenic and osteogenic
differentiation potential compared with HD-derived BM-
MSCs (Figures 1B and 1C). Differences were evident by
both qualitatively, limited staining with oil red O and aliz-
arin red, and quantitatively by a significant decrease in the
expression of early and latemaster regulator genes of adipo-
genic (cEBPa, PPAR) and osteogenic (ALPL, Osterix, and
Ostepontin) differentiation (Figures 1B and 1C). Overall,
these data demonstrate that bona fide BM-MSC cultures
can be successfully derived from LR-, IR- and HR-AML pa-
tients; however, HR-AML BM-MSC cultures show intrinsic
impairments in their ability to form adipocytes and osteo-
cytes in vitro.
We next assessed whether BM-MSCs from LR-, IR- and
HR-AML patients had a similar proliferative potential to
HD-derived BM-MSCs by assessing both their growth rate
in vitro and their clonogenic potential. BM-MSCs from
Table 1. Biological and Cytogenetic-Molecular Characteristics of Blasts and BM-MSCs from Diagnostic AML Patients
Patient ID Diagnostic Cytogenetics Molecular
Age
(years) Gender Blasts (%) Risk
Cytogenetic/Molecular
Alteration in BM-MSCs
AML01 AML-M4 46, XY, inv(16) Cbfb-MYH11 20 M 56 low negative
AML02 AML-M5 46, XY, inv(16) Cbfb-MYH11 1 M 50 low negative
AML03 AML-M2 46, XY, t(8;21) AML1-ETO 30 M 39 low ND
AML04 AML 46, XX NPM1MUT, IDH1MUT 20 F 92 low negative
AML05 AML 46, XY NPM1MUT 18 M 32 low negative
AML06 AML 46, XY, t(5;15) cEBPaMUT 66 M 15 low negative
AML07 AML-M4 46, XX NPM1MUT 37 F 80 low negative
AML08 AML-M3 46, XX t(15;17) PML-RARa 59 F 90 low negative
AML09 AML-5b 46, XX NPM1MUT 70 F 34 low ND
AML10 AML-M3 46, XY, t(15;17) PML-RARa 27 M 92 low negative
AML11 AML 46, XY NPM1MUT 81 M 45 low ND
AML12 AML 46, XY NPM1MUT 80 M 49 low negative
AML13 AML 46, XX NPM1MUT 71 F 45 low ND
AML14 AML 46, XX NPM1MUT 78 F 67 low negative
AML15 AML-M3 46, XY, t(15;17) PML-RARa 25 M 90 low negative
AML16 AML-M3 46, XY, inv(16) Cbfb-MYH11 27 M 40 low negative
AML17 AML 46, XY – 10 M 92 int ND
AML18 AML 46, XY – 81 M 35 int ND
AML19 AML 46, XY – 77 M 45 int ND
AML20 AML 46, XX – 61 F 71 int ND
AML21 AML-M4 46, XY – 86 M 50 int ND
AML22 AML 46, XX – 52 F 79 int ND
AML23 AML 46, XY – 78 M 60 int ND
AML24 AML-M4 46, XX – 44 F 65 int ND
AML25 AML 46, XY – 61 M 1 int ND
AML26 AML-M7 46, XY – 60 M 60 int ND
AML27 AML 46, XY – 56 M 40 int ND
AML28 AML-M5 46, XX, t(11;19) MLL-ENL 48 F 77 high negative
AML29 AML 45, XY, 7 – 80 M 85 high negative
AML30 AML-M2 46, XX, t(8;21) AML1-ETO, FLT3-ITD 4 F 40 high negative/negative
AML31 AML-M4 46, XX, t(9;11) MLL-AF9 63 F 90 high negative
AML32 AML 45, XY, 7 – 73 M 15 high negative
AML33 AML-M5 46, XY NPM1MUT, FLT3del 77 M 80 high negative/negative
AML34 AML-M5 46, XX NPM1MUT, FLT3-ITD 65 F 90 high negative/negative
(Continued on next page)
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Table 1. Continued
Patient ID Diagnostic Cytogenetics Molecular
Age
(years) Gender Blasts (%) Risk
Cytogenetic/Molecular
Alteration in BM-MSCs
AML35 AML-M1 46, XX NPM1MUT, FLT3-ITD 73 F 90 high negative
AML36 AML 46, XX, 11q23 MLL-MLL (PTD) 74 F 70 high ND
AML37 AML-M1 46, XX, t(9;11) MLL-AF9 77 F 80 high negative
AML38 AML 45, XY, 7 – 69 M 22 high negative
AML39 AML-M4 46, XY NPM1MUT, FLT3MUT, WT1MUT 42 M 99 high negative
AML40 AML CK – 35 M 80 high negative
AML41 AML 47, XY (+mar) FLT3 D835MUT 81 M 47 high negative
AML42 AML-M2 46, XX MLL-PTD+ 76 F 40 high negative
AML43 AML 46, XY, 7q – 53 M 56 high negative
AML44 AML-M4 47, XY, +8 WT1+, TP53 exon 6+ 69 M 35 high ND
AML45 AML-M4 46, XX MLL-PTD+ 68 F 65 high negative
AML46 AML 46, XX FLT3-ITD 8 F 95 high negative
HD01 normal 46, XX – 37 F 0 HD ND
HD02 normal 46, XY – 34 M 0 HD ND
HD03 normal 46, XY – 41 M 0 HD ND
HD04 normal 46, XY – 42 M 0 HD ND
HD05 normal 46, XY – 42 M 0 HD ND
HD06 normal 46, XX – 34 F 0 HD ND
HD07 normal 46, XY – 28 M 0 HD ND
HD08 normal 46, XX – 49 F 0 HD ND
HD09 normal 46, XY – 56 M 0 HD ND
HD10 normal 46, XX – 34 F 0 HD ND
HD, healthy donor; CK, complex karyotype; int, intermediate risk; M, male; F, female; –, no mutations found for FLT3, NPM1, cEBPa, WT, and IDH1; ND, not
determined.both HD and the three molecularly different subgroups of
AML grew similarly, achieving sic to seven population dou-
blings over five passages (42–45 days, Figure 2A). Interest-
ingly, colony forming unit-fibroblast (CFU-F) activity in
BM derived from LR-, IR- and HR-AML patients was 2-fold
greater (p = 0.04) than that detected from HDs (Figure 2B).
These data indicate that BM-MSCs can be detected at
a greater frequency from all molecular AML subgroups
compared with HDs but that this is not related to a greater
proliferative capacity of BM-MSCs ex vivo.
BM-MSCs from Cytogenetically Distinct AML
Subgroups Are Highly Immunosuppressive
Increasing evidence suggests a potential contribution of
the stroma milieu and immune escape to therapy resis-1576 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017tance in AML (Klopp et al., 2011). Whether or not
this contribution is in part mediated by BM-MSCs
remains unclear, partially due to the fact that the
immunosuppressive and anti-inflammatory properties of
AML-derived BM-MSCs have yet to be tested. To address
this, we compared the immunosuppressive properties of
the different AML subgroups with HD-derived BM-MSCs.
As a negative control in these experiments, T cells were
co-cultured with transformed BM-MSCs (tMSCs), an
oncogenic cell line derived from primary BM-MSCs
that has been previously demonstrated to lack immuno-
suppressive properties (Funes et al., 2007; Rodriguez
et al., 2014). Using carboxyfluorescein succinimidyl ester
(CFSE) dilution assays to monitor cell division, we found
that AML-derived BM-MSCs suppressed the proliferation
AB
C
Figure 1. Differentiation Capacity of BM-
MSCs from HDs and AML Patients
(A) Phase-contrast morphology of BM-MSCs
from HD and AML patients.
(B) Top: oil red O staining indicative of
adipogenic differentiation potential of BM-
MSCs from HD, LR-, IR-, and HR-AML sub-
jects. Bottom: quantitative expression by
qRT-PCR for the pan-adipogenesis tran-
scription factors cEBPa and PPAR.
(C) Top: alizarin red staining revealing
the osteogenic differentiation capacity of
BM-MSCs from HD, LR-, IR-, and HR-AML
subjects. Bottom: quantitative expression
by qRT-PCR for the pan-osteogenesis
transcription factors ALPL, OSTERIX, and
OSTEOPONTIN. Original magnification is
indicated in microscopy images. n = 30
patients (10 LR-, 10 IR-, and 10 HR-AML)
and n = 10 healthy donor controls.
Error bars indicate the SEM values of the
biological replicates. *p < 0.05.of phytohemagglutinin (PHA)-stimulated human periph-
eral blood mononuclear cells (PBMCs) irrespective of
the molecular subgroup (Figure 3A). In line with previ-
ous studies, the level of immunosuppression (measured
as non-proliferating PHA-stimulated lymphocytes) was
44% ± 20% and 14% ± 8% for HD-derived BM-MSCsand tMSCs, respectively (Figure 3A; Funes et al., 2007; Ro-
driguez et al., 2014; Sanchez et al., 2011). Intriguingly,
AML-derived BM-MSCs had a more robust immunosup-
pressive potential (74% ± 18% for LR-AML, 55% ± 20%
for IR-AML and 66% ± 16% for HR-AML; p < 0.05) than
HD-derived BM-MSCs.Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017 1577
Table 2. Establishment Rate of MSC Cultures from BM-AML According to Cytogenetic/Molecular Risk
Prognostic
Groups Cytogenetics/Molecular
Efficiency of BM-MSC
Culture Establishment
Mean Age
(years) ± SD
Gender
Ratio M/F
Mean
Blasts (%)
LR-AML inv(16)/CBFB-MYH11 3/3 (100%) 44.4 ± 26.8 10/6 57.3 ± 24.8
t(8;21)/AML1-ETO 1/1 (100%)
t(15;17)/PML-RARa 2/3 (67%)
NK (NPMmut,FLT3wt) 6/8 (75%)
t(5;15)/TP53BP1-PDGFRB 1/1 (100%)
IR-AML NK (NPMwt, FLT3wt, cEBPawt) 10/11 (91%) 55.2 ± 27.9 8/3 54.4 ± 24.5
HR-AML CK 7/7 (100%) 59.7 ± 22.9 9/10 66.1 ± 25.9
NK (NPMwt,FLT3mut) 4/5 (83%)
MLL-r (11q23) 5/6 (83%)
NK/NPM1mut, IDH1mut 1/1 (100%)
HD 10/10 (100%) 40 ± 8 6/4 0
NK, normal karyotype; CK, complex karyotype; MLL-r, MLL rearranged; MUT, mutated; HR, high risk; IR, intermediate risk; LR, low risk; HD, healthy donor.To further confirm this result, we analyzed the cytokine
profile in PHA/lipopolysaccharide (LPS)-activated human
PBMCs co-cultured or not with the different BM-MSC sub-
groups (Lopez-Millan et al., 2017). The production of
master pro-inflammatory cytokines, such as interferon g
(IFN-g), tumor necrosis factor a (TNF-a), IL-1b, and IL-8,
was significantly inhibited by LR-, IR- and HR-AML BM-
MSCs, whereas the levels of the non-inflammatory cyto-
kine IL-6 were unchanged (Figure 3B). Consistent with
the results of the CSFE/proliferation assay of stimulated
PBMCs, AML-derived BM-MSCs were superior to HD-
derived BM-MSCs in inhibiting the secretion of these pro-
inflammatory cytokines (Figure 3B). Conversely, LR- and
HR-AML BM-MSCs significantly increased the levels of
the anti-inflammatory cytokine IL-10 compared with HD-
derived BM-MSCs (Figure 3B). These in vitro data show
that AML-derived BM-MSCs are immunosuppressive/anti-
inflammatory by both inhibiting lymphocyte proliferation
and modulating cytokine secretion.
BM-MSCs have been shown to confer in vitro therapy
resistance to leukemic blasts (Iwamoto et al., 2007; Klopp
et al., 2011; Konopleva et al., 2002), suggesting that
MSCs in BM niches have anti-apoptotic/protective proper-
ties that could provide a safe haven for leukemic cells. To
determine whether this property is retained in AML-
derived BM-MSCs, we treated AML HL60 cells with cytara-
bine/idarubicin for 72 hr in the presence or absence of
immunosuppressive BM-MSCs (HD- and AML-derived).
To determine whether BM-MSCs which have lost immuno-
suppressive potential had the capacity to confer resistance,
we also measured the chemoprotective capacity of tMSCs.1578 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017BM-MSCs from HD and AML (irrespective of the cyto-
genetic risk-group) were equally chemoprotective and
conferred a significantly higher level of resistance to AML
cells compared with tMSCs, as shown by a significant
reduction of apoptosis (Figure 3C).
IL-10 Secretion Levels from AML-Derived BM-MSCs
Correlate Directly with Patient Overall Survival
Since a primary method of action for MSCs is the secretion
of growth factors and cytokines, we next used Luminex
assays to evaluate the concentration of various factors
secreted to the media of cultured AML- and HD-derived
BM-MSCs in the presence of unstimulated PBMCs. Secreted
levels of TNF-a, IFN-g, IL-1b, IL-8, IL-6, and IL-10 were
variable from donor to donor such that no significant dif-
ferences were detected between HD- and AML-derived
BM-MSCs.More interestingly, however, when the cytokine
concentrations produced by AML-derived BM-MSCs were
included in a multivariate analysis, IL-10 secretion levels
by AML-derived BM-MSCs and patient age were the only
variables that had a significant impact on patient outcomes
among all the clinical-biological variables analyzed, which
include eight cytokines, molecular/cytogenetic risk stratifi-
cation, white blood cell (WCB) counts, and percentage of
BM blasts, among others. Specifically, a patient age of <60
versus R60 years (Figure 4A) and levels of IL-10 (<125
versus R125 pg/mL) released by AML-derived BM-MSCs
(Figure 4B) had a significant effect on patient OS (p =
0.03) while other variables such as WBC count (Figure 4C,
p = 0.22) and percentage of BM blasts (Figure 4D, p = 0.525)
did not. As such, the median survival of patients with
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Figure 2. Functional Characterization of
BM-MSCs from HDs and AML Patients
(A) Proliferation measured as population
doublings of BM-MSC cultures from LR-, IR-,
and HR-BM-MSC compared with BM-MSCs
from HD. Inset represents patient vari-
ability. n = 46 patients (16 LR-, 11 IR-, and
19 HR-AML) and n = 10 healthy donor
controls.
(B) Clonogenic capacity of BM-MSCs (num-
ber of CFU per 1,000 cells seeded) from HD
and LR-, IR- and HR-AML subjects. p < 0.05.
Right: representative crystal violet staining
of BM-MSC-CFU/colonies from HD- and AML-
derived BM-MSCs. n = 40 patients (13 LR-,
10 IR-, and 17 HR-AML) and n = 10 healthy
donor controls. Error bars indicate the SEM
values of the biological replicates.[IL-10] R 125 pg/mL was 11 months, compared with
32 months for those patients with [IL-10] < 125 pg/mL.
The multivariate analysis confirmed that the secretion of
high levels of IL-10 shortened the survival of our patients
independent of other variables. The hazard ratios for age
and IL-10 concentration were 4.0 (95% confidence interval
[CI] = 1.5–10.4, p = 0.026) and 5.1 (95% CI = 1.8–14.8, p =
0.013), respectively. Collectively these data represent evi-
dence linking a property of BM-MSCs with clinical disease
outcomes in treated AML patients.
BM-MSCs from AML Patients Do Not Harbor Tumor-
Specific Cytogenetic/Molecular Alterations
BM-MSCs play a role in the pathogenesis of a variety of
hematologic malignances (Garcia-Castro et al., 2008). The
cellular origin of leukemia-specific fusion genes and recur-
rent genetic abnormalities is difficult to ascertain; however,
the finding of tumor-specific genetic alterations in eitherthe MSC or the endothelial BM compartment in CML,
MDS, ALL, and MM suggest that stromal cells may be
in part tumor related, and that such oncogenic insults
may arise in a population of pre-hematopoietic precursors
(Blau et al., 2007; Corre et al., 2007; Lopez-Villar et al.,
2009; Menendez et al., 2009; Shalapour et al., 2010; Streu-
bel et al., 2004;Walkley et al., 2007). We screened BM-MSC
cultures from the majority of AML patients in a search
for the molecular abnormalities found in the leukemia
population at diagnosis. Using fluorescence in situ
hybridization (FISH), G-banding, and PCR-based analysis,
no diagnostic molecular/cytogenetic hallmarks, including
CBFB-MYH11, AML1-ETO, PML-RARa, MLL rearrange-
ments, complex karyotypes, trisomies, and monosomy 7,
MLL-PTD, FLT3-ITD, FLT3 point mutations, NPM, wild-
type, cEBPa, and TP53 mutations, were detected in BM-
MSCs from a heterogeneous cohort of AML patients
(Table 1). These data suggest that AML-derived BM-MSCsStem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017 1579
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are not tumor related and that common AML-specific
oncogenic drivers do not arise in pre-hematopoietic
precursors.DISCUSSION
The BMmicroenvironment plays a role in the pathogenesis
of a variety of hematologic malignances, including acute
leukemia, MM, lymphomas, and MDS (Blau et al., 2007;
Corre et al., 2007; Lopez-Villar et al., 2009; Menendez
et al., 2009; Shalapour et al., 2010; Streubel et al., 2004;
Walkley et al., 2007). MSCs are key components of the
BMmilieu, andmany efforts are being undertaken to assess
their role in several hematopoietic disorders (Garcia-Castro
et al., 2008). BM-MSCs regulate normal hematopoiesis
through cell-cell interaction with HSPCs or via released
paracrine factors within functional BM niches. BM-MSCs
contribute to themaintenance of leukemogenesis/hemato-
poiesis by regulating self-renewal, differentiation, survival,
and apoptosis. In hematopoietic malignances, BM stroma
is likely to be an accomplice to tumor development, pro-
moting an environment that supports the growth and
clonal evolution of malignant cells through as yet unde-
finedmechanisms. Conversely, it may be the leukemic cells
themselveswhich drive the reprogramming of BM-MSCs to
provide a niche that is more permissive to the disease (Gar-
cia-Gomez et al., 2014; Klopp et al., 2011; Medyouf et al.,
2014). Regardless, a clearer understanding of the role of
BM-MSCs in leukemias, and particularly in AML, could
lead to improved treatments that reduce the occurrence
of residual disease and relapse in patients (Iwamoto et al.,
2007; Konopleva et al., 2002).
To date, our capacity to determine the role of BM-MSCs
in AML has been hampered by a poor level of characteriza-
tion and contradictory results (Chandran et al., 2015;
Geyh et al., 2016; Klopp et al., 2011; Le et al., 2016; von
der Heide et al., 2016). Here we report a detailed func-
tional, genetic, and immunological characterization of
BM-MSC cultures from a cohort of 46 diagnostic AMLsFigure 3. In Vitro Immunosuppressive and Anti-Inflammatory Pr
(A) Left: level of immunosuppression measured as percentage of CFSE
PHA and then co-cultured with BM-MSCs from LR-, IR-, and HR-AML
(tMSCs) were used as positive and negative controls, respectively. Righ
cytometry. Representative flow-cytometry histograms of CSFE-labele
patients (11 LR-, 10 IR-, and 14 HR-AML) and n = 10 healthy donor con
replicates.
(B) Concentration of the indicated cytokines in cell-culture supernat
co-cultured with BM-MSCs from 10 HD, 2 tMSCs, and 35 BM-MSCs from
the biological replicates. *p < 0.05.
(C) Similar protective effect of immunosuppressive BM-MSCs from HD
idarubicin cytotoxic treatment of HL60 AML cells. Error bars indicateand ten age-matched HDs. Bona fide MSC cultures were
successfully established from the BM of 90% of AML pa-
tients irrespective of the molecular/cytogenetic subgroup.
BM-MSCs from all molecular AML subgroups showed
intrinsic differences compared with those from HDs,
including a higher clonogenic potential and greater
immune suppressive capacity, while HR-AML-derived
BM-MSCs exhibited further functional impairments
in their adipogenic/osteogenic differentiation potential.
Most importantly, we demonstrate that AML-derived
BM-MSCs do not harbor the tumor-specific cytogenetic/
molecular alterations and provide evidence of a clear clin-
ical link between BM-MSCs and treatment outcomes for
AML patients.
Compared with previous research, our prospective char-
acterization of MSCs from BM of AML patients is unique
in several aspects. First, the large number of patients
analyzed allowed us to address the high level of heteroge-
neity associated with the disease. Accordingly, we were
able to gain insights into the functional, genetic, and
immunosuppressive properties of BM-MSCs derived from
distinct LR, IR, andHR groups (Arber et al., 2016). One clear
distinction in our study of 46 AML patients was that BM-
MSCs from the HR-AML subgroup showed a severe impair-
ment in both adipogenic and osteogenic differentiation
potential. This finding supports a previous study from
Geyh et al. (2016) showing impaired osteogenic differenti-
ation of AML-derived BM-MSCs. However, our data
contrast with a study published by Le et al. (2016), who
reported that AML-derived BM-MSCs have markedly
increased adipogenic differentiation. This may be ex-
plained by the limited cohort of patients (n = 5 LR) used
in their study and underpins the importance of stratifying
AML patients because of the high clinico-biological hetero-
geneity of the disease. Overall, we consider that the large
number of samples analyzed in this study allows for
increased clarity on potential differences in the function
of AML BM-MSCs and suggests that defects in osteogenic
and adipogenic differentiation may play a role in disease
progression from HR subgroups.operties of BM-MSCs from HDs and AML Patients
+ non-proliferating cells. CSFE-labeled PBMCs were stimulated with
subjects for 5 days. BM-MSCs from HD and transformed BM-MSCs
t: the number of cycling (CSFEmild/low) cells was determined by flow
d PBMCs: R1, proliferating cells; R2 non-proliferating cells. n = 35
trols. *p < 0.05. Error bars indicate the SEM values of the biological
ants determined by Luminex Multiplex assays. PBMCs from HD were
LR-, IR-, and HR-AML subjects. Error bars indicate the SEM values of
and AML (LR-, IR- and HR-) individuals, but not tMSCs, to Ara-C/
the SEM values of the biological replicates. *p < 0.05.
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B Figure 4. Five-Year OS Kaplan-Meier
Curve Reveals that Higher Production of
IL-10 by BM-MSCs Is Independently Asso-
ciated with Shorter OS in AML
Impact of patient’s age (A), IL-10-secreted
levels by BM-MSCs (B), white blood cell
counts (WBC) (C), and percentage of blasts
in the BM (D) on OS. n = 35 patients (11 LR-,
10 IR-, and 14 HR-AML) and n = 10 healthy
donor controls.Leukemia-specific translocations and recurrent genetic
abnormalities have been found in bothMSCs and endothe-
lial cells in B-cell ALL,MM, and lymphoma, suggesting that
stromal cells may be in part tumor related and that such
oncogenic insults may arise in a population of pre-hemato-
poietic precursors such as early mesodermal precursors or
hemangioblast-like progenitors (Blau et al., 2007; Corre
et al., 2007; Lopez-Villar et al., 2009; Menendez et al.,
2009; Prieto et al., 2016; Shalapour et al., 2010; Streubel
et al., 2004;Walkley et al., 2007). The presence of AML-spe-
cific molecular hallmarks in BM-MSCs from AML patients
has not been analyzed to date. We show that AML-derived
BM-MSCs do not harbor tumor-specific cytogenetic/molec-
ular alterations found at diagnosis, such as CBFB-MYH11,
AML1-ETO, PML-RARa,MLL rearrangements, complex kar-
yotypes, trisomies, andmonosomy 7, MLL-PTD, FLT3-ITD,
FLT3 point mutations, NPM, wild-type, cEBPa, and TP53
mutations. Thesedata confirmthatBM-MSCsarenot tumor
related and that the cell of origin for AML may be an early
hematopoietic stem cell or a more committed myeloid
progenitor. Three out of the 46 AMLs were pediatric cases,
yet still their BM-MSCs were devoid of tumor-specific cyto-
genetic/molecular alterations, further emphasizing that
even in those pediatric cases in which genetic drivers may
have a prenatal origin during in utero hematopoietic devel-
opment, the target cell for transformation seems to be an
ontogenically early HSPC (Greaves and Wiemels, 2003;
Menendez et al., 2009; Sanjuan-Pla et al., 2015).1582 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017BM-MSCs secrete cytokines that can suppress immune
cell activation as well as enhance proliferation, vasculogen-
esis, migration, and chemoresistance, all key processes
that may permit tumor progression and immune escape
(Bernardo and Fibbe, 2013; Klopp et al., 2011). From the
current level of understanding it is hypothesized that
BM-MSCs play a role in maintaining hematopoiesis and
supporting leukemogenesis in some hematopoietic malig-
nancies (Iwamoto et al., 2007;Klopp et al., 2011; Konopleva
et al., 2002). This may be mediated through one or more of
the multiple functions attributed to MSCs, of which im-
mune modulation is arguably the most clinically relevant
(Knaan-Shanzer, 2014; Najar et al., 2016). In the case of
solid tumors, there is concrete evidence that immune sup-
pression mediated by the stromal environment enables
cancer cell growth (Turley et al., 2015). A similar role for
MSCs in AML, however, is less clear. This is partially due
to the fact that no studyhas addressed the immunosuppres-
sive and anti-inflammatory nature of BM-MSCs derived
from AML patients. Our in vitro studies demonstrate that
regardless of the molecular subgroup, AML-derived BM-
MSCs aremore highly immunosuppressive/anti-inflamma-
tory than those derived from HDs. Immunosuppressive
properties ofMSCs can be considered a double-edged sword
based on evidence suggesting that MSCs could be respon-
sible for the enhanced tumor growth and chemoresistance
in solid tumors and leukemia (Djouadet al., 2003; Lowet al.,
2015). It is interesting to note that T cell dysfunction has
been reported inAMLpatients. The increased immune-sup-
pressive function of BM-MSCs noted in our study implies
that a potential role for BM-MSCs in the loss of T cell func-
tion in these patients warrants further investigation.
BM-MSCs have also been shown in vitro to protect ALL/
AML cells from cytotoxic therapy (Iwamoto et al., 2007;
Kloppet al., 2011;Konopleva et al., 2002).Here, co-culturing
BM-MSCs with AML cells reduced apoptosis in AML cells in
response to chemotherapy. Our data also reveal that while
AML-derived BM-MSCs show functional differences from
HD-derived MSCs, they maintain a similar capacity to pro-
tect leukemic cells from chemotherapy. Interestingly, BM-
MSC-derived adipocytes have been implicated in leukemic
cell apoptosis in response to doxorubicin through a cell con-
tact-dependent mechanism (Klopp et al., 2011). Thus, our
finding thatHR-AML-derivedBM-MSCsarehighly immuno-
suppressive and chemoprotective, coupled with a marked
impairment in adipogenic potential, may be associated
with the ultimate poorer prognosis of HR-AML patients
who frequently fail to respond to therapy or relapse.
Two of the most intriguing findings of our study are that
BM-MSCs do not harbor the molecular alterations associ-
ated with the disease and that the concentration of IL-10
secreted by BM-MSCs in culture is directly linked to patient
outcome. The nature of the molecular and (epi)genetic
alterations of BM-MSCs for the pathogenesis of AML
has just begun to be elucidated in a very recent single-
center study using genetic, transcriptional, and epigenetic
genome-wide omics approaches (von der Heide et al.,
2016). While studies such as these may shed further light
on the genetic and epigenetic changes involved in AML
pathogenesis and disease relapse, our study goes further to
demonstrate that any potential functional changes in
MSCs thatmaybe contributing to thedisease arenot related
to the presence of the key molecular alterations associated
with the different AML subgroups. More strikingly, how-
ever, our data provide comprehensive clinical evidence of
a link between BM-MSC behaviors in vitro and response
to treatment inAMLpatients.Ourfinding that the secretion
of higher concentrations of IL-10 by BM-MSCs indepen-
dently shortened the survivalof ourpatients implies adirect
role for BM-MSCs in AML and relapse from treatment. The
contribution of potential molecular and cellular alterations
of BM-MSCs to the pathogenesis of AML demands further
integrative-functional studies, whichmay ultimately facili-
tate the design of niche-directed therapies in AML.EXPERIMENTAL PROCEDURES
Patients
Fresh BM aspirates were obtained at time of disease presentation
from 46 patients (27 males and 19 females; median age of 53 ±
25 years) with cytogenetically different AML. Patients were diag-nosed in the following hospitals: Hospital Clı´nico San Carlos (Ma-
drid, Spain), Hospital Virgen de Arrixaca (Murcia, Spain), Hospital
Universitario de Gran Canaria (Las Palmas, Spain), ICO-Hospital
Germans Trias i Pujol (Badalona, Spain), and Hospital Santa Creu
i San Pau (Barcelona, Spain). In addition, BM from ten age-
matched HD (6 males and 4 females; median age of 40 ± 8 years)
were used as controls. The diagnosis of AML was based on
French-American-British (FAB) (Bennett et al., 1985) and World
Health Organization (WHO) classifications (Dohner et al., 2010;
Grimwade, 2002; Swerdlow et al., 2008). AML was classified
as low-risk AML (LR-AML, displaying favorable cytogenetics/
molecular features), intermediate-risk AML (IR-AML, with normal
karyotype and lacking mutations in NPM, FLT3, or cEBPa), and
high-risk AML (HR-AML, displaying unfavorable cytogenetics/
molecular features) disease. Table 1 shows the main cytogenetic/
molecular diagnostics and other clinical-biological features of
each patient. Table 2 shows the success of establishing BM-MSC
cultures from the three distinct AML subtypes. The study was
IRB-approved by the Clinic Hospital of Barcelona and samples
were accessed upon signed informed consent.
Isolation and Expansion of BM Mesenchymal Stem/
Stromal Cells
Mononuclear cells (MNCs) from BM were isolated by centrifuga-
tion using Ficoll-Paque Plus (GE Healthcare) density gradients.
MNCs were seeded at 2 3 105 cells/cm2 and maintained in a hu-
midified atmosphere with 5% CO2 at 37
C for 48 hr, after which
non-adherent cells were washed off and fresh medium was added.
Adherent cells at >85% confluence were trypsinized and replated
at 1.6 3 103 cells/cm2 (Bueno et al., 2014; Menendez et al., 2009;
Rodriguez et al., 2012, 2013). The resulting BM-MSC cultures
were maintained in Advanced DMEM (Gibco) supplemented
with 10% fetal calf serum (Invitrogen), L-glutamine, and peni-
cillin-streptomycin-amphotericin B (Gibco). BM-MSC cultures
were assessed daily for changes in growth rates and morphology.
Established BM-MSC cultures were extensively characterized at
p1–p3 (Bueno et al., 2014; Menendez et al., 2009; Rodriguez
et al., 2012, 2013).
Cytotoxic Assay
Irradiated BM-MSCs (2 3 104 cells/well) were co-cultured with the
AML cell line HL60 (2 3 104 cells/well) in a 96-well plate. Co-cul-
tures were treated or not with cytarabine (77 nM) and idarubicin
(7 nM) for 72 hr. Floating cells were collected, washed in PBS,
and stained with anti-CD33-APC (Becton Dickinson catalog no.
551378) for 15 min. After washing, cells were stained with An-
nexin-V-PE and 7-ADD (PE Annexin V Apoptosis Detection Kit I
[RUO], BD cat. no. 559763) as described by Romero-Moya et al.
(2013). Apoptotic cells (Annexin V+) were analyzed within the
CD33+ population using a FACSCanto-II flow cytometer.
Molecular and Cytogenetic Analysis of BM-MSCs
Derived from AML Patients
To evaluate whether themolecular-cytogenetic hallmarks found in
diagnostic AML blasts were present in corresponding BM-MSCs,
we analyzed cells at p2–p3 as described previously (Bueno et al.,
2009; Catalina et al., 2008; Menendez et al., 2009). In brief,Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017 1583
structural/numerical chromosome alterations were assessed by
conventional G-banding (Bueno et al., 2009; Catalina et al.,
2008; Menendez et al., 2009). Chromosomes were visualized using
modified Wright staining. At least 20 metaphases were analyzed
using a conventional microscope and IKAROS software (Metasys-
tems). Metaphases of cells were GTG-banded and karyotyped in
accordance with the International System for Human Cytogenetic
Nomenclature recommendations (Standing Committee on Hu-
man Cytogenetic Nomenclature et al., 1985). Balanced transloca-
tions were analyzed by FISH using commercially available probes
(Vysis). CBFB-MYH11, AML1-ETO, and PML-RARa fusions were
detected using locus-specific LSI Dual Color probes, whereas MLL
fusions were analyzed using LSI MLL Dual Color probes. At least
500 nuclei were analyzed. Slides were analyzed under a fluores-
cence microscope equipped with appropriate filters using ISIS
software (Metasystems). Molecular analyses of the AML-associated
mutations in NPM1, FLT3, cEBPa,MLL, TP53, andWT1 genes were
performed using established protocols (Lasa et al., 2009; Nomde-
deu et al., 2011, 2013).
Statistical Analysis
Median and mean values and their SDs and ranges were calcu-
lated for each variable under study using SPSS software. All
key data were supported by statistical tests performed on at least
three independent replicates and are expressed as mean ± SEM.
Statistical comparisons between experimental groups were per-
formed with either paired or unpaired Student’s t test, as appro-
priate. Kaplan-Meier curves for OS were plotted and the effect of
the different clinico-biological variables (molecular/cytogenetic
classification, WBC, % of BM blasts, age, cytogenetics, MSC dif-
ferentiation potential, CFU, and levels of TNF-a, IFN-g, IL-1b,
IL-8, IL-10, IL-6, IL-2, and IL-4) assessed using the log rank
test. The Cox proportional hazards regression model was used
to explore the independent effect of variables that showed a
significant influence on OS by univariate analysis. The statis-
tical significance cutoff was corrected according to the Bonfer-
roni method. Statistical significance was defined as a p value
of <0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and one figure and can be foundwith this article online
at http://dx.doi.org/10.1016/j.stemcr.2017.04.019.
AUTHOR CONTRIBUTIONS
R.D.d.l.G. conceived the study, designed and performed experi-
ments, analyzed data, and wrote the manuscript. P.M. and
M.R.-M. conceived the study, designed experiments, analyzed
data, and wrote the manuscript. B.L.-M., C.B., J.C., M.J., L.B.,
L.P., J.R.L., and J.D. performed experiments and analyzed data.
M.G.-C., S.V., A.C., J.N., J.L.F., and E.A. provided leukemic samples
and clinical data.
ACKNOWLEDGMENTS
This work was supported by Health Canada’s Genomics Research
and Development Initiative Phase VI (H4080-144541-2014-2019)1584 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017to P.M., M.R.-M., and J.R.L.; the European Research Council
(CoG-2014-646903), the RTC-2016-4603-1, the Obra Social La
Caixa-Fundacio` Josep Carreras and the Generalitat de Catalunya
(SGR330) to P.M.; the Asociacio´n Espan˜ola Contra el Ca´ncer
(AECC-CI-2015) and the ISCIII (PI14-01191) to C.B. and the
‘‘Fundacio´n Hay Esperanza’’ to E.A. P.M. and J.L.F. are investigators
of the SpanishCell Therapy cooperative network (TERCEL).We are
indebted to Dominique Patry from Health Canada for his assis-
tance with the Luminex experiments. We would like to thank
Dr. Kenneth McCreath for editorial support.
Received: January 13, 2017
Revised: April 15, 2017
Accepted: April 18, 2017
Published: May 18, 2017REFERENCES
Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le
Beau, M.M., Bloomfield, C.D., Cazzola, M., and Vardiman, J.W.
(2016). The 2016 revision to theWorld Health Organization classi-
fication of myeloid neoplasms and acute leukemia. Blood 127,
2391–2405.
Bene,M.C.,Grimwade,D.,Haferlach,C.,Haferlach,T., Zini,G., and
European, L. (2015). Leukemia diagnosis: today and tomorrow. Eur.
J. Haematol. 95, 365–373.
Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton,
D.A., Gralnick, H.R., and Sultan, C. (1985). Proposed revised
criteria for the classification of acute myeloid leukemia. A report
of the French-American-British Cooperative Group. Ann. Intern.
Med. 103, 620–625.
Bernardo, M.E., and Fibbe, W.E. (2013). Mesenchymal stromal
cells: sensors and switchers of inflammation. Cell Stem Cell 13,
392–402.
Blau, O., Hofmann,W.K., Baldus, C.D., Thiel, G., Serbent, V., Schu-
mann, E., Thiel, E., and Blau, I.W. (2007). Chromosomal aberra-
tions in bone marrow mesenchymal stroma cells from patients
with myelodysplastic syndrome and acute myeloblastic leukemia.
Exp. Hematol. 35, 221–229.
Blau, O., Baldus, C.D., Hofmann, W.K., Thiel, G., Nolte, F., Bur-
meister, T., Turkmen, S., Benlasfer, O., Schumann, E., Sindram,
A., et al. (2011). Mesenchymal stromal cells of myelodysplastic
syndrome and acute myeloid leukemia patients have distinct ge-
netic abnormalities compared with leukemic blasts. Blood 118,
5583–5592.
Bueno, C., Catalina, P., Melen, G.J., Montes, R., Sanchez, L., Ligero,
G., Garcia-Perez, J.L., and Menendez, P. (2009). Etoposide induces
MLL rearrangements and other chromosomal abnormalities in
human embryonic stem cells. Carcinogenesis 30, 1628–1637.
Bueno, C., Roldan, M., Anguita, E., Romero-Moya, D., Martin-An-
tonio, B., Rosu-Myles, M., del Canizo, C., Campos, F., Garcia, R.,
Gomez-Casares, M., et al. (2014). Bone marrow mesenchymal
stem cells from patients with aplastic anemia maintain functional
and immune properties and do not contribute to the pathogenesis
of the disease. Haematologica 99, 1168–1175.
Catalina, P., Montes, R., Ligero, G., Sanchez, L., de la Cueva, T.,
Bueno, C., Leone, P.E., andMenendez, P. (2008). Human ESCs pre-
disposition to karyotypic instability: is a matter of culture adapta-
tion or differential vulnerability among hESC lines due to inherent
properties? Mol. Cancer 7, 76.
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-
Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Reme, T., et al.
(2007). Bone marrow mesenchymal stem cells are abnormal in
multiple myeloma. Leukemia 21, 1079–1088.
Chandran, P., Le, Y., Li, Y., Sabloff, M., Mehic, J., Rosu-Myles, M.,
and Allan, D.S. (2015). Mesenchymal stromal cells from patients
with acute myeloid leukemia have altered capacity to expand
differentiated hematopoietic progenitors. Leuk. Res. 39, 486–493.
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J.,
Noel, D., and Jorgensen, C. (2003). Immunosuppressive effect of
mesenchymal stem cells favors tumor growth in allogeneic ani-
mals. Blood 102, 3837–3844.
Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T.,
Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A.,
et al. (2010). Diagnosis and management of acute myeloid
leukemia in adults: recommendations from an international
expert panel, on behalf of the European LeukemiaNet. Blood
115, 453–474.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Mar-
ini, F., Krause, D., Deans, R., Keating, A., Prockop, D., and Horwitz,
E. (2006). Minimal criteria for defining multipotent mesenchymal
stromal cells. The International Society for Cellular Therapy posi-
tion statement. Cytotherapy 8, 315–317.
Funes, J.M., Quintero, M., Henderson, S., Martinez, D., Qureshi,
U., Westwood, C., Clements, M.O., Bourboulia, D., Pedley, R.B.,
Moncada, S., et al. (2007). Transformation of humanmesenchymal
stem cells increases their dependency on oxidative phosphoryla-
tion for energy production. Proc. Natl. Acad. Sci. USA 104, 6223–
6228.
Garcia-Castro, J., Trigueros, C., Madrenas, J., Perez-Simon, J.A., Ro-
driguez, R., andMenendez, P. (2008). Mesenchymal stem cells and
their use as cell replacement therapy and disease modelling tool.
J. Cell. Mol. Med. 12, 2552–2565.
Garcia-Gomez, I., Elvira, G., Zapata, A.G., Lamana, M.L., Ramirez,
M., Castro, J.G., Arranz, M.G., Vicente, A., Bueren, J., and Garcia-
Olmo, D. (2010). Mesenchymal stem cells: biological properties
and clinical applications. Expert Opin. Biol. Ther. 10, 1453–1468.
Garcia-Gomez, A., De Las Rivas, J., Ocio, E.M., Diaz-Rodriguez, E.,
Montero, J.C., Martin, M., Blanco, J.F., Sanchez-Guijo, F.M., Pan-
diella, A., San Miguel, J.F., et al. (2014). Transcriptomic profile
induced in bone marrow mesenchymal stromal cells after interac-
tion with multiple myeloma cells: implications in myeloma pro-
gression and myeloma bone disease. Oncotarget 5, 8284–8305.
Geyh, S., Rodriguez-Paredes, M., Jager, P., Khandanpour, C., Ca-
deddu, R.P., Gutekunst, J., Wilk, C.M., Fenk, R., Zilkens, C., Herm-
sen, D., et al. (2016). Functional inhibition of mesenchymal
stromal cells in acute myeloid leukemia. Leukemia 30, 683–691.
Gonzalo-Gil, E., Perez-Lorenzo, M.J., Galindo, M., Diaz de la Guar-
dia, R., Lopez-Millan, B., Bueno, C., Menendez, P., Pablos, J.L., and
Criado, G. (2016). Human embryonic stem cell-derived mesen-chymal stromal cells ameliorate collagen-induced arthritis by
inducing host-derived indoleamine 2,3 dioxygenase. Arthritis
Res. Ther. 18, 77.
Greaves,M.F., andWiemels, J. (2003).Originsof chromosometrans-
locations in childhood leukaemia. Nat. Rev. Cancer 3, 639–649.
Grimwade, D. (2002). Screening for core binding factor gene rear-
rangements in acute myeloid leukemia. Leukemia 16, 964–969.
Grimwade, D., Ivey, A., and Huntly, B.J. (2016). Molecular land-
scape of acute myeloid leukemia in younger adults and its clinical
relevance. Blood 127, 29–41.
Hills, R.K., Ivey, A., and Grimwade, D.; UK National Cancer
Research Institute (NCRI) AMLWorkingGroup (2016). Assessment
of minimal residual disease in standard-risk AML. N. Engl. J. Med.
375, e9.
Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cor-
tenbach, I., Marini, F.C., Deans, R.J., Krause, D.S., Keating, A.,
and International Society for Cellular Therapy. (2005). Clarifica-
tion of the nomenclature for MSC: the international society for
cellular therapy position statement. Cytotherapy 7, 393–395.
Iwamoto, S., Mihara, K., Downing, J.R., Pui, C.H., and Campana,
D. (2007). Mesenchymal cells regulate the response of acute
lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117,
1049–1057.
Klopp, A.H., Gupta, A., Spaeth, E., Andreeff,M., andMarini, F., 3rd.
(2011). Concise review: dissecting a discrepancy in the literature:
do mesenchymal stem cells support or suppress tumor growth?
Stem Cells 29, 11–19.
Knaan-Shanzer, S. (2014). Concise review: the immune status of
mesenchymal stem cells and its relevance for therapeutic applica-
tion. Stem Cells 32, 603–608.
Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A.Y., Afanasiev,
B.V., and Andreeff, M. (2002). Stromal cells prevent apoptosis of
AML cells by up-regulation of anti-apoptotic proteins. Leukemia
16, 1713–1724.
Konopleva, M., Tabe, Y., Zeng, Z., and Andreeff, M. (2009). Thera-
peutic targeting of microenvironmental interactions in leukemia:
mechanisms and approaches. Drug Resist. Updat. 12, 103–113.
Lasa, A., Carricondo, M., Estivill, C., Bussaglia, E., Gich, I., Brunet,
S., Aventin, A., Sierra, J., and Nomdedeu, J.F. (2009). WT1 moni-
toring in core binding factor AML: comparison with specific
chimeric products. Leuk. Res. 33, 1643–1649.
Le, Y., Fraineau, S., Chandran, P., Sabloff, M., Brand, M., Lavoie,
J.R., Gagne, R., Rosu-Myles, M., Yauk, C.L., Richardson, R.B.,
et al. (2016). Adipogenic mesenchymal stromal cells from bone
marrow and their hematopoietic supportive role: towards under-
standing the permissive marrow microenvironment in acute
myeloid leukemia. Stem Cell Rev. 12, 235–244.
Lopez-Millan, B., Diaz de la Guardia, R., Roca-Ho, H., Garcia Her-
rero, C.M., Lavoie, J.R., Rosu-Myles, M., Gonzalez-Rey, E., O’Valle,
F., Criado, G., Delgado, M., et al. (2017). Therapeutic effect of the
immunomodulatory drug lenalidomide, but not pomalidomide,
in experimental models of rheumatoid arthritis and inflammatory
bowel disease. Exp. Mol. Med. 49, e290.
Lopez-Villar, O., Garcia, J.L., Sanchez-Guijo, F.M., Robledo, C., Vil-
laron,E.M.,Hernandez-Campo,P.,Lopez-Holgado,N.,Diez-Campelo,Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017 1585
M., Barbado,M.V., Perez-Simon, J.A., et al. (2009). Both expanded and
uncultured mesenchymal stem cells from MDS patients are genomi-
cally abnormal, showing a specific genetic profile for the 5q- syn-
drome. Leukemia 23, 664–672.
Low, J.H., Ramdas, P., and Radhakrishnan, A.K. (2015).Modulatory
effects of mesenchymal stem cells on leucocytes and leukemic
cells: a double-edged sword? Blood Cells Mol. Dis. 55, 351–357.
Medinger, M., Lengerke, C., and Passweg, J. (2016). Novel thera-
peutic options in acutemyeloid leukemia. Leuk. Res. Rep. 6, 39–49.
Medyouf, H., Mossner, M., Jann, J.C., Nolte, F., Raffel, S., Herr-
mann, C., Lier, A., Eisen, C., Nowak, V., Zens, B., et al. (2014). Mye-
lodysplastic cells in patients reprogrammesenchymal stromal cells
to establish a transplantable stem cell niche disease unit. Cell Stem
Cell 14, 824–837.
Menendez, P., Catalina, P., Rodriguez, R., Melen, G.J., Bueno, C.,
Arriero, M., Garcia-Sanchez, F., Lassaletta, A., Garcia-Sanz, R., and
Garcia-Castro, J. (2009). Bone marrow mesenchymal stem cells
from infants with MLL-AF4+ acute leukemia harbor and express
the MLL-AF4 fusion gene. J. Exp. Med. 206, 3131–3141.
Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M.,
and Lagneaux, L. (2016).Mesenchymal stromal cells and immuno-
modulation: a gathering of regulatory immune cells. Cytotherapy
18, 160–171.
Nomdedeu, J., Bussaglia, E., Villamor, N., Martinez, C., Esteve, J.,
Tormo, M., Estivill, C., Queipo, M.P., Guardia, R., Carricondo,
M., et al. (2011). Immunophenotype of acute myeloid leukemia
with NPMmutations: prognostic impact of the leukemic compart-
ment size. Leuk. Res. 35, 163–168.
Nomdedeu, J.F., Hoyos, M., Carricondo, M., Bussaglia, E., Estivill,
C., Esteve, J., Tormo, M., Duarte, R., Salamero, O., de Llano, M.P.,
et al. (2013). BonemarrowWT1 levels at diagnosis, post-induction
and post-intensification in adult de novo AML. Leukemia 27,
2157–2164.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R.,
Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and
Marshak, D.R. (1999). Multilineage potential of adult human
mesenchymal stem cells. Science 284, 143–147.
Prieto, C., Stam, R.W., Agraz-Doblas, A., Ballerini, P., Camos, M.,
Castano, J., Marschalek, R., Bursen, A., Varela, I., Bueno, C., et al.
(2016). Activated KRAS cooperates with MLL-AF4 to promote ex-
tramedullary engraftment and migration of cord blood CD34+
HSPC but is insufficient to initiate leukemia. Cancer Res. 76,
2478–2489.
Rodriguez, R., Rubio, R., andMenendez, P. (2012). Modeling sarco-
magenesis using multipotent mesenchymal stem cells. Cell Res.
22, 62–77.
Rodriguez, R., Tornin, J., Suarez, C., Astudillo, A., Rubio, R., Yauk,
C., Williams, A., Rosu-Myles, M., Funes, J.M., Boshoff, C., et al.
(2013). Expression of FUS-CHOP fusion protein in immortalized/
transformed human mesenchymal stem cells drives mixoid lipo-
sarcoma formation. Stem Cells 31, 2061–2072.
Rodriguez, R., Rosu-Myles, M., Arauzo-Bravo, M., Horrillo, A., Pan,
Q., Gonzalez-Rey, E., Delgado, M., and Menendez, P. (2014).
Human bone marrow stromal cells lose immunosuppressive and1586 Stem Cell Reports j Vol. 8 j 1573–1586 j June 6, 2017anti-inflammatory properties upon oncogenic transformation.
Stem Cell Rep. 3, 606–619.
Romero-Moya, D., Bueno, C., Montes, R., Navarro-Montero, O.,
Iborra, F.J., Lopez, L.C., Martin, M., and Menendez, P. (2013).
Cord blood-derived CD34+ hematopoietic cells with low mito-
chondrial mass are enriched in hematopoietic repopulating stem
cell function. Haematologica 98, 1022–1029.
Sanchez, L., Gutierrez-Aranda, I., Ligero, G., Rubio, R., Munoz-Lo-
pez, M., Garcia-Perez, J.L., Ramos, V., Real, P.J., Bueno, C., Rodri-
guez, R., et al. (2011). Enrichment of human ESC-derived multipo-
tent mesenchymal stem cells with immunosuppressive and
anti-inflammatory properties capable to protect against experi-
mental inflammatory bowel disease. Stem Cells 29, 251–262.
Sanjuan-Pla, A., Bueno, C., Prieto, C., Acha, P., Stam, R.W., Mar-
schalek, R., and Menendez, P. (2015). Revisiting the biology of in-
fant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood
126, 2676–2685.
Schepers, K., Campbell, T.B., and Passegue, E. (2015). Normal and
leukemic stem cell niches: insights and therapeutic opportunities.
Cell Stem Cell 16, 254–267.
Shalapour, S., Eckert, C., Seeger, K., Pfau, M., Prada, J., Henze, G.,
Blankenstein, T., and Kammertoens, T. (2010). Leukemia-associ-
ated genetic aberrations in mesenchymal stem cells of children
with acute lymphoblastic leukemia. J. Mol. Med. 88, 249–265.
Sison, E.A., and Brown, P. (2011). The bonemarrowmicroenviron-
ment and leukemia: biology and therapeutic targeting. Expert Rev.
Hematol. 4, 271–283.
Standing Committee on Human Cytogenetic Nomenclature,
Harnden, D.G., Klinger, H.P., and March of Dimes Birth Defects
Foundation. (1985). ISCN 1985: An International System for Hu-
man Cytogenetic Nomenclature (1985): Report of the Standing
Committee on Human Cytogenetic Nomenclature (Karger).
Streubel, B., Chott, A., Huber, D., Exner, M., Jager, U., Wagner, O.,
and Schwarzinger, I. (2004). Lymphoma-specific genetic aberra-
tions in microvascular endothelial cells in B-cell lymphomas.
N. Engl. J. Med. 351, 250–259.
Swerdlow, S.H., International Agency for Research on Cancer, and
World Health Organization. (2008). WHO Classification of Tu-
mours of Haematopoietic and Lymphoid Tissues, Fourth Edition
(International Agency for Research on Cancer).
Tabe, Y., and Konopleva, M. (2014). Advances in understanding
the leukaemia microenvironment. Br. J. Haematol. 164, 767–778.
Turley, S.J., Cremasco, V., and Astarita, J.L. (2015). Immunological
hallmarks of stromal cells in the tumour microenvironment. Na-
ture reviews. Immunology 15, 669–682.
von der Heide, E.K., Neumann, M., Vosberg, S., James, A.R.,
Schroeder, M.P., Tanchez, J.O., Isaakidis, K., Schlee, C., Luther,
M., Johrens, K., et al. (2016). Molecular alterations in bonemarrow
mesenchymal stromal cells derived from acute myeloid leukemia
patients. Leukemia http://dx.doi.org/10.1038/leu.2016.324.
Walkley, C.R., Olsen, G.H., Dworkin, S., Fabb, S.A., Swann, J.,
McArthur, G.A., Westmoreland, S.V., Chambon, P., Scadden,
D.T., and Purton, L.E. (2007). A microenvironment-induced
myeloproliferative syndrome caused by retinoic acid receptor
gamma deficiency. Cell 129, 1097–1110.
